Bilen MA, et al. - The authors investigated how the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), and the platelet-to-lymphocyte ratio (PLR) are associated with clinical outcomes of patients with advanced-stage cancer who received immunotherapy (IO). They performed a retrospective review of 90 patients with advanced cancer who received treatment on phase 1 clinical trials of IO-based treatment regimens. They log-transformed and treated NLR, MLR, and PLR values as continuous variables for each patient. Outcomes revealed that baseline and early changes in these values were strongly correlated with clinical outcomes in patients who received IO-based treatment regimens on phase 1 trials. Hence they suggest considering these values for inclusion when risk stratifying patients enrolled onto phase 1 clinical trials of IO agents.